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Artemisinin-based combination (ACT) therapy is the mainstay for malaria treatment. However, Plasmodium parasite with decreased 
susceptibility to ACT has emerged. Hence, it is imperative to discover new drugs or explore new drug combinations that can decrease 
Plasmodium parasite resistance. This study assessed the antiplasmodial activity of dihydroartemisinin-piperaquine- doxycycline (D-P-
DX) on mice infected with Plasmodium berghei. Swiss albino mice (25-30g) of both sexes inoculated with 1x107 Plasmodium berghei 
intraperitoneally were used. The mice were randomly grouped and orally treated with DX (2.2 mg/kg), D-P (1.71/13.7 mg/kg) and D-P-
DX daily in curative, suppressive and prophylactic studies. The negative and the positive controls were treated daily with normal saline 
(0.2mL) and chloroquine (CQ) (10mg/kg), respectively. After treatment, blood samples were assessed for percentage parasitemia, 
hematological and lipid parameters. The mice were observed for mean survival time. D-P, DX, and D-P-DX produced significant 
decreases in percentage parasitemia at p<0.05, p<0.01 and p<0.001, respectively when compared to negative control.  In the curative 
study, D-P, DX, and D-P-DX produced 64.9%, 71.1%, and 93.6% parasitemia inhibitions when compared to 75.0% inhibition produced 
by CQ.  Plasmodium berghei -induced alterations in packed cell volume, white blood cells, red blood cells, hemoglobin, high-density 
lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were significantly restored by DX 
(p<0.05) and D-P (p<0.01) and D-P-DX (p<0.001) when compared to the negative control. D-P-DX showed significant antiplasmodial 
activity against Plasmodium berghei- infected mice. It may be clinically useful for the treatment of malaria. 
 





World Health Organization (WHO) estimates that nearly 
half of the world’s population lived in malaria endemic 
areas (WHO, 2016). Malaria, a Plasmodium parasite 
infection is one of the greatest health challenges in 
tropical regions, despite the availability of antimalarial 
drugs, mosquito repellents and insecticide-treated nets. 
Malaria chemotherapy remains a major focus of 
research, and new molecules are being discovered prior 
to the emergence of drug-resistant strains of 
Plasmodium parasite (Gaillard et al., 2015). The use of 
antimalarial drugs is faced with the development of 
resistance from Plasmodium falciparum in primarily 
endemic areas. Other challenges include financial costs, 
contraindications, and clinical tolerance (Gaillard et al., 
2015). 
Doxycycline (DX), a broad-spectrum bacteriostatic 
agent is synthetically obtained from naturally occurring 
tetracyclines produced by Streptomyces sp. (McEvoy et 
al., 2008). It acts by binding to several proteins in the 
30S ribosomal small subunit and to different ribonucleic 
acids in the 16S ribosomal RNA. In addition to its 
antimicrobial activity, it is a partially efficacious 
prophylactic drug with activity against liver stage of 
Plasmodium and blood schizontocides. It is highly 
effective for the prevention of malaria. The U.S. Food 
and Drug Administration (FDA) approved the use of DX 
for prophylaxis of Plasmodium falciparum in short-term 
travelers to areas with chloroquine or pyrimethamine-
sulfadoxine-resistant strains (Tan et al., 2011). DX can 
be used for the treatment of malaria in children less than 
8 years old and non-pregnant adults in combination with 
quinine sulfate for uncomplicated and chloroquine-
resistant Plasmodium falciparum. It is also used with 
primaquine and quinine sulfate for uncomplicated 
chloroquine-resistant Plasmodium vivax and with 
parenteral quinidine for severe malaria (Griffith et al., 
2007). 
Artemisinin derivatives are highly potent with fast 
acting antiplasmodial activity. However, due to short 
half-life, and Plasmodium parasite resistance to 
artemisinin derivatives and older antimalarial drugs, 
artemisinin derivatives are often combined with partner 
drugs with longer half-life for fast clearance of malaria 
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artemisinin-based combination therapies (ACTs), which 
have become the mainstay for the treatment of malaria 
especially in malaria endemic regions (Basco et al., 
2017). However, Plasmodium parasites with decreased 
susceptibility to ACTs’ have emerged due to both 
decreased susceptibility to artemisinins and partner 
drugs (Leang et al., 2013; Sanders et al., 2014). Also, 
dihydroartemisinin-piperaquine (D-P), one of the 
currently used ACTs, which is efficacious against 
malaria (Tayler et al., 2020) and is being considered for 
the prevention of malaria in pregnancy (Kakuru et al., 
2016; Desai et al., 2016) has experienced Plasmodium 
resistance in malaria endemic regions. Plasmodium 
resistance was attributed to decreased susceptibility to 
both piperaquine and dihyroartemisinin (Amaratunga et 
al., 2016; Amato et al., 2017). Hence this study aimed to 
evaluate if the antiplasmodial effect of D-P can be 




MATERIALS AND METHODS 
 
Animals, Drugs and Parasites 
Swiss albino mice of both sexes (25-30 g) used for this 
study were sourced from the animal husbandry of the 
Department of Pharmacology, Faculty of Basic Clinical 
Sciences, University of Port Harcourt, Rivers State. The 
mice were housed in cages at temperature 20oC with 
cycles of 12 h light/12 h darkness. The mice were 
acclimated for 2 weeks and fed with food pellets and 
given water ad libitum. CQ was manufactured by Alben 
Healthcare Ind Ltd, D-P was manufactured by Bliss 
GVS Pharma Ltd India whereas DX was manufactured 
by Ranbaxy Laboratories Ltd, India. Doses were 
selected based on previous studies: CQ (10mg/kg) 
(Somsak et al., 2018), DX (2.2 mg/kg) (Gaillard et al., 
2015) and D-P (1.71/13.7 mg/kg) (Yavo et al., 2011). 
CQ-sensitive Plasmodium berghei (P. berghei) (NK65) 
was used. P. berghei was obtained from Nigerian 
Institute of Medical Research, Yaba, Lagos. Mice used 
were inoculated intraperitoneally (i.p.) with 0.2 mL of 
infected red blood cells (RBCs) containing P. berghei 
(1 × 107) obtained from the donor mice. 
 
Evaluation of Antiplasmodial Activity  
 Evaluation of curative activity 
Curative activity was performed as reported by Ryley 
and Peters (1970). Twenty-five Swiss albino mice were 
inoculated i.p with blood containing 1 × 107. P. berghei 
and grouped into 5 of 5 mice each. The first two groups, 
AI (Negative control) and A2 (Positive control) were 
orally treated with normal saline (0.2mL) and CQ 
(10mg/kg) daily for 4 days, respectively. Groups A3-A5 
were orally treated with DX (2.2 mg/kg), D-P (1.71/13.7 
mg/kg) and D-P-DX daily for 4 days, respectively. On 
day 5, tail blood samples were collected from the mice; 
thin blood films were produced on slides and stained 
with Giemsa stain and viewed with the aid of a 
microscope. Evaluations for percentage parasitemia and 




Number of parasitized red blood cells (RBCs) × 100




(%Parasitemia of negative control − %Parasitemia of treated group)  × 100




 Evaluation of prophylactic activity  
Prophylactic test was performed using an established 
method described by Peters (1965). Twenty-five Swiss 
albino mice were assigned to 5 groups of 5 mice each. 
Group BI served as the negative control and group B2 
served as the positive control and were orally treated 
with normal saline (0.2ml) and CQ (10mg/kg) daily for 
4 days, respectively. Groups B3-B5 were orally treated 
with DX (2.2 mg/kg), D-P (1.71/13.7 mg/kg) and D-P-
DX daily for 4 days, respectively. On day 5, the mice 
were inoculated i.p with 0.2 mL of infected blood 
containing 1x107P. berghei. After, 3 days, tail blood 
samples were collected and percentage parasitemia and 
inhibitions were calculated using the formula above. 
 
 Evaluation of suppressive activity  
Suppressive test was carried out as described by Knight 
and Peters (1980). Twenty-five mice were selected and 
inoculated i.p with blood containing 1x107 P. berghei. 
After 3 h, the mice were randomized into 5 groups of 5 
mice each. The first two groups, CI (Negative control) 
and C2 (Positive control) were orally treated with 
normal saline (0.2mL) and CQ (10mg/kg) daily for 4 
days, respectively. Groups C3-C5 were orally treated 
with DX (2.2 mg/kg), D-P (1.71/13.7 mg/kg) and D-P-
DX daily for 4 days, respectively. On day 5, tail blood 
samples were collected and evaluated for percentage 
parasitemia and inhibitions using the formula above. 
 
Evaluation of Biochemical Parameters 
Blood samples were collected from the mice used for the 
curative test and evaluated for white blood cells 
(WBCs), hemoglobin (HB), packed cell volume (PCV), 
red blood cells (RBCs), triglyceride (TG), total 
cholesterol (CHOL), and high-density lipoprotein 








Results as mean ± S EM (standard error of mean). Data 
was analyzed using one-way analysis of variance 
(ANOVA) and Tukey’s test. Differences between means 







Treatment with DX, D-P, and D-P-DX significantly 
decreased percentage parasitemia levels at p<0.05, 
p<0.01 and p<0.001, respectively when compared to the 
negative control (Table 1). The observed parasitemia 
inhibitions produced by DX, D-P, and D-P-DX and CQ 
were 64.9%, 71.1%, 93.6%, and 75.0%, respectively 
(Table 2). MST was significantly prolonged in mice 
treated with DX, D-P, and D-P-DX at p<0.05, p<0.01, 
and p<0.001, respectively when compared to the 
negative control (Table 1). 
 
Suppressive Activity 
Percentage parasitemia levels were significantly 
decreased in mice treated with DX, D-P and D-P-DX at 
p<0.05, p<0.01, and p<0.001, respectively when 
compared to the negative control (Table 2). Treatment 
with DX, D-P and D-P-DX produced 66.5%, 75.0%, and 
95.1% parasitemia inhibitions, respectively whereas CQ 
produced 81.9% parasitemia inhibition (Table 2). 
Significant prolongation of MST in DX, D-P and D-P-
DX-treated mice occurred at p<0.05, p<0.01 and 
p<0.001, respectively when compared to negative 
control (Table 2).  
Prophylactic Activity 
The prophylactic test showed significant decreases in 
percentage parasitemia levels in mice treated with DX 
(p<0.05), D-P (p<0.01) and D-P-DX (p<0.001) when 
compared to the negative control (Table 3). The 
percentage parasitemia inhibitions produced by DX, D-P 
and D-P-DX were 65.1%, 86.8%, and 98.9%, 
respectively while CQ produced an inhibition of 85.7% 
(Table 3). MST was prolonged in DX, D-P, and D-P-
DX-treated mice. This occurred at p<0.05, p<0.01, and 
p<0.001, respectively when compared to the negative 
control (Table 3).  
 
Determination of Mean Survival Time  
The mice in the control and the treated groups were 
observed for mortality and expressed in days. Mortality 
represented as mean survival time (MST) was calculated 
using the formula bellow. 
 
𝑀𝑆𝑇 =
Sum of survival time of all mice in a group (days)
Total number of mice in that group
 
 
Hematological and Lipid Parameters 
In P. berghei-infected mice, TG, CHOL, LDL-C and 
WBCs increased whereas HB, PCV, RBCs and HDL-C 
decreased significantly (p<0.001) when compared to the 
normal control (Tables 4 and 5). On the other hand, TG, 
CHOL, LDL-C WBCs levels were decreased whereas 
HB, PCV, RBC and HDL-C levels were increased 
significantly in mice treated with DX, D-P, and D-P-DX 
at p<0.05, p<0.01 and p<0.001, respectively when 





Table 1. Curative antiplasmodial effect of dihydroartemisinin-piperaquine-doxycycline on mice infected with Plasmodium berghei. 
 
Treatment % Parasitemia % Inhibition MST (Days) 
PC 35.10±3.00 0.0 9.22±0.18 
CQ  8.78±1.54a 75.0 27.62±2.39 a. 
DX 12.30±1.27b 64.9 14.15±1.66b 
D-P 10.11±1.11a 71.1 25.83±2.65 a 
D-P-DX 2.25±0.15c 93.6 36.96±3.48 c 
Data presented as ± SEM, n= 5, PC: Negative control, CQ: Chloroquine, DX: Doxycycline, D-P: Dihydroartemisinin-piperaquine, MST: Mean survival 
time. a p<0.01, b p<0.05, c p<0.001 Significant different when compared to PC, SEM: Standard error mean. 
 
 
Table 2. Suppressive antiplasmodial effect of dihydroartemisinin-piperaquine-doxycycline on mice infected with Plasmodium berghei. 
 
Treatment % Parasitemia % Inhibition MST(Days) 
PC 17.60±2.54 0.0 9.40±0.33 
CQ  3.19±0.01a 81.9 31.61±2.72a 
DX 5.90±0.08b 66.5 20.47±2.67 b 
D-P 4.40±0.09a 75.0 29.73±3.11 a 
D-P-DX 0.86±0.07c 95.1 37.12±3,29 c 
Data presented as ± SEM, n= 5, PC: Negative control, CQ: Chloroquine, DX: Doxycycline, D-P: Dihydroartemisinin-piperaquine, MST: Mean survival 
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Table 3. Prophylactic antiplasmodial effect of dihydroartemisinin-piperaquine-doxycycline on mice infected with Plasmodium berghei. 
 
Treatment % Parasitemia % Inhibition MST (Days) 
PC 15.80±1.47 0.0 9.79±0.22 
CQ  2.58±0.06a 85.7 33.43±2.53 a 
DX 5.51±0.07b 65.1 22.75±3.57 b 
D-P 3.03±0.04a 86.8 30.91±2.89 a 
D-P-DX 0.17±0.08c 98.9 38.02±3.86 c 
Data presented as ± SEM, n= 5, PC: Negative control, CQ: Chloroquine, DX: Doxycycline, D-P: Dihydroartemisinin-piperaquine, MST: Mean survival 
time a p<0.01, b p<0.05, c p<0.001 Significant different when compared to PC, SEM: Standard error mean. 
 
 
Table 4. Effect of dihydroartemisinin-piperaquine-doxycycline on hematologic parameters of mice infected Plasmodium berghei. 
 
Treatment RBC (x106) WBC (cells/L) PCV (%) Hb (g/dL) 
NC 6.83±0.33 7.55±0.09 60.91±5.91 16.93±1.35 
PC 3.21±0.43a 15.71±1.55a 26.72±3.45a 6.01±0.17a 
CQ  5.44±0.28b 9.44±0.19b 44.21±4.33b 13.45±1.38b 
DX 4.37±0.27c 11.00±0.37c 31.94±3.47c 10.73±0.81c 
D-P 5.40±0.11b 9.57±0.16b 42.62±3.67b 13.07±1.11b 
D-P-DX 6.61±0.32d 7.25±0.01d 55.9±4.41d 16.72±1.37d 
Data presented as ± SEM, n= 5, NC: Normal control, PC: Negative control, CQ: Chloroquine, DX: Doxycycline, D-P: Dihydroartemisinin-piperaquine, 
MST: Mean survival time, RBCs: Red blood cell, WBCs: White blood cell, PCV: Packed cell volume, Hb: Haemoglobin. a p<0.001 significant difference 
when compared to NC, b p<0.01, c p<0.05, d p<0.001 Significant difference when compared to PC, SEM: Standard error mean. 
 
 
Table 5. Effect of dihydroartemisinin-piperaquine on lipid parameters of mice infected with Plasmodium berghei. 
 
Group TG (mg/dL) TCHOL (mg/dL) HDL-C (mg/dL) LDL (mg/dL) 
NC 80.8±7.03 110.8±11.4 50.4±4.00 44.2±3.11 
PC 250.3±18.9a 273.4±18.0 a 22.2±1.41 a 201.1±18. a 
CQ 150.1±5.87 b 181.6±22.4 b 39.7±4.63 b 111.9±11.6 b 
DX 200.7±3.03 c 220.0±12.0 c 30.6±4.22 c 149.3±15.0 c 
D-P 159.0±4.87b 170.7±13.5b 38.7±4.00b 100.2±12.5b 
D-P-DX 97.4±8.88d 127.7±10.6 d 47.9±5.43d 60.3±10.1d 
Data presented as mean ± SEM, n= 5, NC: Normal control, PC: Negative control, CQ: Chloroquine, DX: Doxycycline, D-P: dihydroartemisinin-
piperaquine, TG: Tryglyceride, TCHOL: Total cholesterol, HDL: High density lipoproteins, LDL: Low density lipoprotein.  a p<0.001 Significant 






Malaria is a major health challenge in developing 
countries of sub-Saharan Africa and South East Asia. 
The emergence of widespread resistance of Plasmodium 
species to most antimalarial drugs, the increasing 
insecticide resistance by mosquitoes, and the lack of 
vaccines have made the fight against malaria seriously 
tasking (Beeson et al., 2016; Joseph et al., 2020). Hence 
there is an urgent need to discover alternative drugs with 
novel modes of action or a combination of currently 
existing antimalarial drugs to overcome these 
challenges. The present study, assessed whether 
antimalarial activity of D-P can be augmented by DX in 
mice infected with P. berghei. This study used in-
vivo model, because it takes into cognizance the possible 
prodrug effect and the involvement of the immune 
system in eradicating malaria infection. P. berghei has 
been used in antiplasmodial studies in predicting 
experimental treatment outcomes and hence was 
appropriately used for the study (Satish et al., 2017). 
This study used suppressive test which determines the 
activity of a drug candidate on early infection and 
curative test, which evaluates the curative activity of a 
drug candidate on established infection (Mekonnen, 
2015; Hiben et al., 2016). In the present study, in the 
curative test, D-P-DX decreased percentage parasitemia 
levels most when compared to individual doses of D-P, 
DX and CQ. The observed parasitemia inhibitions in the 
curative test were 64.9%, 71.1%, 93.6% in DX, D-P, 
and D-P-DX-treated mice, respectively. Also, in the 
suppressive and prophylactic tests, best decreases in 
percentage parasitemia levels occurred in D-P-DX-
treated mice in comparison to individual doses of DX, 
D-P, and CQ. In the suppressive test, 66.5%, 75.0%, and 
95.1%, parasitemia inhibitions were observed in DX, D-
P, and D-P-DX treated mice respectively. In view of the 
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present study, the ability of D-P-DX to prolong MST in 
mice was also evaluated. Treatment with D-P-DX 
prolonged MST in the curative, prophylactic and 
suppressive tests. The prolongation of MST by D-P-DX 
was best when compared to individual doses of DX, D-
P, and CQ. Hematological abnormalities like anemia 
caused by erythrocyte destruction are common 
characteristics of P. berghei-infected mice. Rodent 
malaria causes parasite-induced decrease in PCV, which 
occurs approximately 48 h post-infection (Nardos and 
Makonnen, 2017). In the present study, notable signs of 
anemia marked by low levels of HB, PCV RBCs and 
increased WBCs levels were observed in P. berghei-
infected mice. However, P. berghei- induced anemia 
was curtailed in D-P-DX treated mice when compared to 
individual doses of DX, D-P, and CQ. Studies have 
reported that changes in serum lipids could be possible 
features of malaria (Visser et al., 2013). The present 
study observed elevated TCHOL, TG, and LDL-C and 
decreased HDL-C levels in P. berghei-infected mice. 
However, D-P-DX restored serum lipid characterized by 
decreased TCHOL, TG, LDL-C and increased HDL-C 
levels.  The observed antiplasmodial effect of D-P-DX 
may be due to different modes of antiplasmodial activity 
of the partner drugs. Dihydroartemisinin acts through 
the cleavage of the endoperoxide bridge and the 
production of free radicals (Meshnick, 1994). 
Piperaquine is suggested to have similar mode of action 
as CQ (Meshnick, 1994). In parasite food vacuole, 
concentrated CQ binds free hematin forming CQ-
hematin complex. This interferes with enzymatic 
processes in the parasite causing parasite death (Tärning 
et al., 2007). The antiplasmodial mode of action of DX 
is not clear, but studies suggested the inhibition of 
mitochondrial protein, nucleotides and deoxynucleotides 
syntheses in Plasmodium (Yeo et al., 1997; 





This study showed that D-P-DX produced the best 
antiplasmodial activity in P. berghei-infected mice when 
compared to individual doses of D-P, DX and CQ. Also, 
alterations in lipid profile and hematological parameters 
were best restored by D-P-DX when compared to 
individual doses of D-P, DX and CQ. This shows that 
D-P-DX may be an effective antimalarial drug 
combination. 
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